During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

If a progression-free survival readout later this year is positive, the firm will pursue approval in HLA-A2-negative metastatic uveal melanoma.

NEW YORK – A first-in-human Phase I trial is underway testing Atavistik Bio's ATV-1601 in patients with AKT1 E17K-mutated solid tumors, the Cambridge, Massachusetts-based company announced this week.

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.

NEW YORK – Xoma Royalty on Monday said it will acquire Lava Therapeutics and discontinue developing its lead leukemia treatment candidate LAVA-1266, a CD123-targeted bispecific gamma delta T-cell ...

BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.